InvestorsHub Logo

DewDiligence

05/06/21 5:41 PM

#35 RE: DewDiligence #34

ASMB 1Q21 results:

https://finance.yahoo.com/news/assembly-biosciences-reports-first-quarter-200500927.html

Cash, cash equivalents and marketable securities were $214.9 million as of March 31, 2021, compared to $216.4 million as of December 31, 2020. This result includes $34.1 million of net proceeds from the issuance of common shares under Assembly Bio’s at-the-market (ATM) program.

No CC.

DewDiligence

09/01/21 4:20 PM

#36 RE: DewDiligence #34

ASMB discontinues HBV core inhibitor, ABI-H2158 due_to_liver_tox:

https://www.globenewswire.com/news-release/2021/09/01/2290389/16259/en/Assembly-Bio-Announces-Decision-to-Discontinue-Clinical-Development-of-ABI-H2158.html

This company can’t seem to get anything right! Please see #msg-162149575, #msg-159327881 for background info.